- 1 Short Chain Fatty Acids mechanisms and functional importance in the gut.
- 2 Camille Martin-Gallausiaux<sup>1</sup>\*, Ludovica Marinelli<sup>2</sup>\*, Hervé M. Blottière<sup>2,3</sup>, Pierre Larraufie<sup>4</sup>
- 3 and Nicolas Lapaque<sup>2#</sup>
- <sup>4</sup> Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette,
- 5 Luxembourg
- 6 <sup>2</sup> Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, 78350,
- 7 Jouy-en-Josas, France
- 8 <sup>3</sup> Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, MetaGenoPoliS, 78350,
- 9 Jouy-en-Josas, France
- <sup>4</sup> Université Paris-Saclay, AgroParisTech, INRAE, UMR PNCA, 75005, Paris, France
- \* These authors contributed equally to this work
- # Corresponding author: Nicolas Lapaque nicolas.lapaque@inrae.fr
- Running title: Short Chain Fatty Acids mechanisms and functions
- 14 Keywords: SCFA, microbiota, gut

# 15 Abstract

- In recent years, the importance of the gut microbiota in human health has been revealed and
- many publications have highlighted its role as a key component of human physiology. Owing
- 18 to the use of modern sequencing approaches, the characterization of the microbiome in healthy
- individuals and in disease has demonstrated a disturbance of the microbiota, or dysbiosis,
- 20 associated with pathological conditions. Microbiota establishes a symbiotic crosstalk with their
- 21 host: commensal microbes benefit from the nutrient-rich environment provided by the gut and
- 22 the microbiota produces hundreds of proteins and metabolites that modulate key functions of
- 23 the host, including nutrient processing, maintenance of energy homeostasis and immune system
- 24 development. Many bacteria-derived metabolites originate from dietary sources. Among them,
- an important role has been attributed to the metabolites derived from the bacterial fermentation
- of dietary fibers, namely the short chain fatty acids (SCFAs) linking host nutrition to intestinal

homeostasis maintenance. SCFAs are an important fuel for intestinal epithelial cells (IEC) and regulate IEC functions through different mechanisms to modulate their proliferation, differentiation as well as functions of subpopulations such as enteroendocrine cells, to impact gut motility and to strengthen the gut barrier functions as well as host metabolism. Recent findings show that SCFAs, and in particular butyrate, also have important intestinal and immuno-modulatory functions. In this review, we discuss the mechanisms and the impact of SCFAs on gut functions and host immunity and consequently on human health.

# Introduction

35

Humans are colonized, at birth, by bacteria, archaea, fungi and viruses, which are collectively 36 37 called the microbiota. Distinct microbiota inhabit all epithelial surfaces of the body: skin, oral cavity, respiratory, gastrointestinal and reproductive tracks (1); with the largest and most diverse 38 39 microbiota residing in the colon. The intestinal microbiota is composed of 100 trillions of bacteria which represent ~25 times as many genes as our own *Homo sapiens* genome. The 40 41 diversity and complexity of the microbiota is influenced by the host genetic background, the 42 diet and the environment. Reciprocally, this microbiota encodes thousands of genes absent in 43 human genome that exert diverse functions often associated with beneficial physiological effects for its host <sup>(2-4)</sup>. From this close symbiotic relationship emerged the notion that humans 44 45 and their microbiota form a composite organism, namely a holobiont (5). Advances in nextgeneration sequencing and bioinformatics tools have shown that this relationship is far more 46 complex than anticipated. Indeed, over the last decade, studies highlighted that perturbation of 47 the microbiota, referred to as dysbiosis, and loss of bacterial diversity affect different host 48 systems, particularly metabolic and immunes processes, that participate to host physiology and 49 pathophysiologic conditions (2). Moreover, growing lines of evidence suggest that the dialogue 50 51 between microbiota and the host systems has a homeostatic role beyond the gut, and contributes directly to the global wellbeing of the host. In agreement with this, animal studies have 52 demonstrated that microbiota is implicated in liver diseases, allergy, diabetes, airway 53 54 hypersensitivity, autoimmune arthritis and even neurological disorders <sup>(6-8)</sup>. The human body has evolved to functionally interact with thousands of naturally occurring or 55 56 microbiota-derived metabolites. Thus, the intestinal microbiome provides an extended repertoire of molecules and metabolites that influence the host health. Amongst those 57 58 molecules, short chain fatty acids (SCFAs), derived from bacteria-dependent hydrolysis of fibers, have attracted considerable attention for their role in host health (figure 1A). Indeed, 59 60 decreased abundance of SCFA-producing bacteria or decreased genomic potential for SCFAproduction have been identified in many studies such type-1 diabetes, type-2 diabetes, liver 61 cirrhosis, inflammatory bowel diseases (IBD) and atherosclerosis (9-14). Here, we aim to provide 62 an overview of bacterial SCFAs production in the gut, their impact on intestinal cells and host 63 64 functions, and their different mechanisms of action.

# SCFAs production and transport

# **Production of SCFAs**

65

66

71

81

87

91

Complex dietary carbohydrates are metabolised by intestinal microbiota through an extensive 67 68 set of enzymes, mostly absent in mammals and belonging to the large family of carbohydrateactive enzymes (CAZyme) (reviewed in (15)). The degradation of dietary fibers by gut 69 microbiota, produces organic acids, gases and large amount of SCFAs. Acetate (C2), 70 propionate (C3) and butyrate (C4) are the main SCFAs produced (60:20:20 mmol/kg in human 72 colon). SCFAs can reach a combined concentration of 50–150 mM mainly in the colon where the microbial biomass is the highest (16-19). Substrates for bacterial fermentation include non-73 digestible carbohydrates derived from dietary fibers such as polysaccharide plant cell walls, 74 resistant starch, soluble oligosaccharide and endogenously products, such as mucin (20). Aside 75 76 bacterial fermentation, SCFAs can also be found in plant oil and animal fats. Butter contains 3 to 4% of butyrate in the form of tributyrin (21). However, when fermentable fibers supply 77 78 decreases, some bacterial species can switch to amino acids and protein fermentation as an alternative energy source, also contributing to SCFAs and branched chain fatty acids (BCFA) 79 production (22, 23). The BCFAs, i.e. isovalerate, 2-methylbutyrate and isobutyrate, are present at 80 lower concentrations than SCFAs and originate only from proteins breakdown. Acetate is a net 82 fermentation product for most gut bacteria while butyrate and propionate are produced by more 83 specific bacterial species. Butyrate is produced from acetate, lactate, amino acids and various carbohydrates via the glycolysis from two different pathways, the butyryl-CoA:acetate CoA-84 85 transferase or the phosphotransbutyrykase and butyrate kinase pathway. Using FISH probes 86 and PCR, Flint and colleagues have shown that specific families belonging to the Clostridiales order (Firmicutes) have the capabilities to produce butyrate: Lachnospiraceae (Coprococcus, 88 Eubacterium, Anaerostipes, Roseburia), Ruminococcaceae (Faecalibacterium, (24-26) 89 Subdoligranulum), Erysipelotrichaceae (Holdemanella) The butyrate-producing capability of Clostridiales has been confirmed using in vitro culture in other genera such as 90 Clostridium, Butyrivibrio, Lachnoclostridium, Marvinbryantia, Oscillibacter, Flavonifractor, Erysipelatoclostridium, Anaerotruncus, Dorea and Blautia, Ruminiclostridium (27, 28). 92 93 Propionate is produced in the gut from various substrate, including amino acids, carbohydrates, lactate and 1,2-propanediol. Hence, most hexoses and pentoses enter the succinate pathway 94 95 and result in succinate production, a precursor of propionate. The succinate pathway is present Bacteroidetes and some Firmicutes, such as the Negativicutes (Veillonella, 96

*Phascolarctobacterium*). Some other Firmicutes, belonging to the Negativicutes (*Megasphera*), the Lachnospiraceae (*Coprococcus*) and the Ruminocaccaceae, use the acrylate pathway, in which lactate is the substrate to produce propionate. The propanediol pathways is present in Proteobacteria and Lachnospiraceae species and use deoxyhexose sugars (*e.g.* fucose) as substrates. The commensal bacterium *Akkermansia muciniphila*, member of the Verrucomicrobia phylum also produces propionate from this later pathway <sup>(29)</sup>. Some bacteria, notably in the Lachnospiraceae family, can produce both propionate and butyrate but from different substrates, *e.g. Roseburia inulivorans* <sup>(30)</sup>.

In vitro experiments have shown that Bacteroides growth is reduced relatively to Firmicutes and Actinobacteria because SCFAs negatively impact Bacteroides at mild acid pH  $^{(31)}$ . Thus, SCFAs production by Firmicutes and Bacteroides may to be regulated by pH variations, with more Firmicutes fermentation in proximal colon (pH $\approx$ 5.6) and conditions favoring Bacteroides fermentation in the distal colon with a more neutral pH (pH $\approx$ 6.3)  $^{(32)}$ . This selective gradient is limiting the propionate production and promoting butyrate formation in the more proximal part of the colon  $^{(24)}$ . Intestinal pH is not the only factor that impact microbiota composition and consequently SCFAs production. Indeed, intestinal gases production (*e.g.* oxygen and hydrogen) and diet composition and intake (*e.g.* type of fibers and iron) have been reported to influence the microbiota composition and the gut SCFAs concentration  $^{(33,34)}$ .

#### SCFAs transport

In the host, SCFAs have distinct roles depending of their absorption and local physiologic concentrations <sup>(35, 36)</sup>. Acetate, propionate and butyrate are weak acids with a pKa of 4.8 for butyrate. In physiological conditions the colonic pH range from 5.5 to 6.7, thus most of SCFAs are in the ionized form and require transporters for absorption <sup>(37, 38)</sup>. SCFA transporters are expressed at different level: in the small intestine: MCT1 (*SLC16A1*), SMCT2 (SLC5A12) and SLC16A7 and in the colon: MCT1 (*SLC16A1*), SMCT2 (*SLC5A12*), SMCT1 (*SL5CA8*) and SLC26A3<sup>(20, 39)</sup>. The transporters MCT1, SMCT1, SLC26A3 show affinities for all three major SCFAs while the other ones are more selective, *e.g.* SMCT2 only transports butyrate. Butyrate is mainly absorbed via MCT-1 that is expressed both at apical and basolateral membrane of colonic epithelial cells <sup>(39, 40)</sup>. From approximately 20mM in gut lumen, butyrate concentration on portal vein reaches a range of 5-10μM. The liver significantly uptakes butyrate as there is almost no splanchnic release <sup>(41, 42)</sup>. Butyrate venous concentration ranges from 0.5μM to 3.3μM <sup>(32)</sup>. Similarly, a larger amount of propionate is found in portal vein, around 32μM but

129 there is only a very small release from the liver. Venous concentration of propionate ranges from 3.8 to 5.4µM. In contrast, acetate is weakly absorbed by epithelial cells and the liver. The 130 portal vein concentration of acetate is 98µM-143µM. Hence, liver efficiently metabolizes the 131 132

butyrate and propionate released by the gut epithelium and avoids any acute increase even in

the case of artificial enema (32, 41). 133

135

136

137

138

139

140

141

142

143

144

145

146

148

149

151

152

153

154

155

156

157

158

159

Cellular uptake of SCFAs in their anionic form are through H<sup>+</sup> or Na<sup>+</sup> coupled transporters. 134

Thus, butyrate transport directly participates in electrolyte absorption with increases of Na<sup>+</sup>

and Cl<sup>-</sup> absorption and release of bicarbonate (HCO<sub>3</sub><sup>-</sup>) in the lumen <sup>(39, 43, 44)</sup>. Interestingly.

electrolytes absorption is region specific due to the different transporter expression levels in

each gut regions (45). Transport of butyrate is electroneutral though SMCT2 (Na+), resulting in

the transport of one Na<sup>+</sup> for each butyrate anion absorbed <sup>(46)</sup>. On the contrary, SMCT1

transport is electrogenic as two Na<sup>+</sup> are transported with one butyrate anion. This results in

electrolytes and water absorption <sup>(47, 48)</sup>. MCT1 is a proton coupled transporter and has no direct

role in ion transport. However, MCT1 indirectly regulates bicarbonate secretion through

Na<sup>+</sup>/H<sup>+</sup> and Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchangers. Interestingly, butyrate modulates the expression of many

transporters including MCT1 and SMCT1, therefore potentially increasing electrolyte

exchanges as well as its own transport. Butyrate blocks Cl<sup>-</sup> secretion by inhibiting NKCC1

expression and increases expression of the Na<sup>+</sup>/H<sup>+</sup> transporter NHE3 through HDAC inhibition

and a SP1/3 dependent pathway (49-52). 147

# Mechanisms

SCFAs receptors

150 The human genome encodes for six potential G protein-coupled receptors (GPCR) sensitive to

SCFAs: GPR41 (FFAR3), GPR42, GPR43 (FFAR2), GPR109a (HCAR2), GPR164 (OR51E1)

and OR51E2. GPR41 and GPR109a are exclusively Gai/o coupled receptors whereas GPR43

can be coupled to either  $G\alpha\beta\gamma q$  and  $G\alpha_{i/o}$  and OR51E2 is  $\alpha s$  coupled <sup>(53)</sup>. GPR42 was recently

identified as a functional GPCR modulating Ca2+ channel flux, but only the GBy pathway

downstream this receptor was explored <sup>(54)</sup>. The GPR41, GPR43 and GPR109a are expressed

in numerous organs including the small and large intestine by various cell types: immune cells,

adipose tissues, heart, skeletal muscle or neurons (20). GPR43 (FFAR2), GPR41 (FFAR3)

recognize acetate, butyrate and propionate with affinities that differ between species, whereas

only butyrate activates GPR109a (Figure 1B) (55-58). Schematically, GPR41 activation by

propionate and butyrate and GPR109a activation by butyrate lead to the inhibition of cAMP (cyclic adenosine monophosphate) accumulation and protein kinase A (PKA) and MAP kinases (ERK et p38) activation. On the other hand, GPR43 is activated by the three main SCFAs with approximately the same affinities. GPR43 engagement stimulates the phospholipase-Cβ, which releases intracellular Ca<sup>2+</sup> and activates the protein kinase C (PKC) in addition to cAMP accumulation inhibition and PKA and ERK activation <sup>(59)</sup>. The highly polymorphic GPR42 is activated by propionate and modulates Ca<sup>2+</sup> by a yet unknown mechanism that could be similar to GPR43 due to the very high homology between these two receptors. In humans, GPR42 is expressed in the colon and in sympathetic ganglia <sup>(54)</sup>. Butyrate is the ligand of GPR164 (OR51E1) expressed all along the gastrointestinal tract and specifically by enteroendocrine cells <sup>(60, 61)</sup>. The olfactory receptor OR51E2 (Olfr78 in mouse) is activated by propionate and acetate and result in cAMP and Ca<sup>2+</sup> increase. Olfr78 is expressed at the gut mucosal level by PYY-positive colonic enteroendocrine cells <sup>(62)</sup>. It is also detected in various tissues, including kidney, blood vessels, lung and specific nerves in the heart and gut <sup>(63)</sup>.

# Transcriptional regulations and post-translational modifications

SCFAs have a broad impact in the host: metabolism, differentiation, proliferation mainly due to their impact on gene regulation. Indeed, several studies revealed that butyrate regulates the expression of 5 to 20% of human genes (64-66). Within the cells, butyrate and propionate exhibit strong inhibition capacity of lysine/histone deacetylase (K/HDAC) activity, with butyrate being more potent than propionate (67, 68). Moreover, butyrate is metabolized into acetyl-CoA which stimulates histone acetyltransferase (HAT) by further enhancing histone acetylation (Figure 1B) (66, 69). By their HDAC inhibitor and HAT stimulatory properties, SCFAs promote posttranslational modification of histones through increasing their acetylation. Histone hyperacetylation leads to an increased accessibility of transcription factors to the promoter regions of targeted genes owing the modulation of their transcription. HDAC inhibition by butyrate does not only up-regulate gene transcription, repression of several genes such as LHR, XIAP or IDO-1 has been reported (27,70). In colonic cell line, 75% of the upregulated genes are dependent of the ATP citrate lyase (ACL) activity and 25% are independent at 0.5mM concentration but the proportion is reversed at high concentration (5mM). This suggests that the gene regulation mechanisms are different, depending on the butyrate concentration. It has been shown that butyrate does not only tune histone acetylation level but also acetylation of other proteins, "K/HDAC" inhibitor, including transcription factors such as SP1 and FOXP3 (71,72). SCFAs derived from the gut microbiota also promote crotonylation through their histone acetylase properties (73). Histone crotonylation is abundant in the small and large bowel epithelium as well as in the brain. Crotonyl-CoA modification of histones is linked to the cell cycle regulation. Moreover, several studies have shown that butyrate also modifies DNA and protein methylation and phosphorylation levels (74-76).

Novel role of butyrate as ligand of transcription factors

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

Beside the extensive described effects of SCFAs on host physiology through GPRs and posttranslational modifications, a novel role emerged for butyrate as ligand of two transcription factors, expanding our knowledge on microbial-host crosstalk. By exploring the mechanisms involved in the microbial modulation of Angiopoietin-like protein 4 (ANGPTL4), Alex and co-workers demonstrated that SCFAs induce ANGPTL4 transcription and secretion through a novel role as selective modulator of peroxisome proliferator-activated receptor γ (PPARγ) in colonic cell lines (77). In this study, Alex and co-workers showed that butyrate promotes, similarly to PPARy ligands, the interactions between PPARy and multiple coactivators and binds into PPARy binding pocket with a conformation similar to the known PPARy agonists, the decanoic acid <sup>(77)</sup>. The evidence suggests, for the first time, an original function of butyrate as ligand for a transcription factor. This original mechanism was also reported for another nuclear transcription factor, the aryl hydrocarbon receptor (AhR) in human colonic cell lines (78). This latter study described a ligand-dependent activation of human AhR by butyrate in synergy with its role as HDAC inhibitor. By using selective ligand antagonists and structural modelling, it emerges that butyrate activates human AhR by binding into its ligand binding pocket similarly to the AhR ligand FICZ (78). Together these reports provide an expanded view of the possible mechanisms for butyrate to modulate human transcription factors activity that might apply to other transcription factors (Figure 1B).

# **Functional impact of SCFA on the host.**

- 217 SCFA, regulators of the gut metabolism, proliferation and differentiation
- SCFAs are efficiently taken up from the gut lumen by the intestinal epithelial cells (IEC) with different fates (Figure 1B). Butyrate is the primary energy source of IECs, being oxidized via the  $\beta$ -oxidation in the mitochondria. This catabolic process represents from 73% to 75% of oxygen consumption by human colonocytes, by which part of butyrate is converted into ketone bodies <sup>(79-81)</sup>. The main substrates of colonocytes are by order of preference, butyrate > ketone

bodies > amino acid > glucose. By using a high level of oxygen, the colonocytes metabolism maintains epithelial hypoxia with an oxygen partial pressure  $[pO_2]$  of less than < 1% oxygen (7.6 mmHg), thus favoring anaerobic commensals (82). The capacity to produce ketone bodies and oxidize butyrate is a crucial difference between the small and large bowel. Epithelial cell butyrate oxidative capacity has been determined in vitro to be between 1 to 5 mM of butyrate, therefore when a greater concentration is available, SCFAs can affect cells functions such as K/HDAC inhibition (69, 83). Moreover, butyrate absorption increases the pyruvate dehydrogenase kinases (PDK) which negatively regulates the pyruvate dehydrogenase (PDH) complex. The PDH decarboxylates pyruvate to produce acetyl-CoA and NADH, both necessary to the tricarboxylic acid (TCA) (84). This dual action pushes the colonocyte metabolism from glycolysis to β-oxidation. After transport into the cells, butyrate enhances oxidative phosphorylation, which consumes oxygen (83). Similarly, it has been demonstrated that fatty acid oxidation is reduced in germ-free mice compared to conventional mice (85). Butyrate is not the only fatty acid metabolized. Acetate is a substrate for cholesterol and fatty acids synthesis and is metabolized in muscles. Propionate is a precursor for the synthesis of glucose in the liver (20, 25, 85). Acetate and butyrate are also major substrates for lipogenesis in rat colonocytes (86).

Through the production of SCFAs, gut microbiota actively communicates with host cells and strongly modulates a variety of cellular mechanisms. Two of the main functions influenced by SCFAs and thus gut microbiota are cell proliferation and differentiation. Indeed, the proliferative activity of crypt epithelial cells as well as the migration of mature epithelial cells along the crypt-villus axis are greatly attenuated in antibiotic-treated and germ-free mice  $^{(87)}$ . At physiological state, butyrate favors cells differentiation and inhibits proliferation. First evidences on IECs were demonstrated on cell lines  $^{(88,89)}$ . In these studies, long term incubation of intestinal cancerous cell lines with SCFAs resulted in differentiated phenotypes coupled to decreased cell proliferation. High concentration of butyrate is associated with inhibition of stem cells and proliferative cells in the crypts, through a HDAC inhibition-dependent binding of FOXO3 to promoters of key genes in the cell cycle  $^{(90)}$ . Butyrate concentration near the crypt base is estimated to be  $50-800\,\mu\text{M}$  dose equivalent  $^{(85,\,91,\,92)}$ . These studies indicate that butyrate concentration is low in the deep crypts and increasing in a gradient along the lumen-to-crypt axis. Butyrate metabolization by differentiated cells on the epithelium plateau may result in a protective depletion in the crypts that is protective for stem cells proliferation. Hence, the crypt

structure is suggested to be an adaptive mechanism protecting the gut epithelial stem cells of

butyrate high concentration found in the lumen <sup>(90)</sup>.

269

270

271

272

273

274

275

276

277

278

279

280

281

282

cAMP levels (99).

Interestingly, butyrate has a dualistic role in epithelial cellular metabolisms: it supports healthy 257 cells as primary energy source for IECs and represses cancerous cells expansion. This is known 258 as the "butyrate paradox" or "Warburg effect" (66). This is explained by a metabolic shift 259 occurring in cancerous cells using preferentially glucose as energy source. The inhibition of 260 cell proliferation is generally characterized by an increase in reactive oxygen species (ROS) 261 production, DNA damages and cell cycle arrest, suggesting that SCFAs initiate apoptosis 262 signaling in cancer cells (93-96). Indeed, through the activation of the pro-apoptotic protein BAX, 263 264 the upregulation of apoptosis-inducing factor-mitochondria associated 1 isoform 6 (AIFM1) 265 and the reduction of mitochondrial membrane potential, SCFAs stimulate the cytochrome c release which drives caspase 3 activation (93). Coherently, the induction of the CDK inhibitors 266 p21 and p27 and the downregulation of heat-shock cognate 71 kDa protein isoform and survival 267 is observed, leading to growth arrest (97, 98). 268

- Another mechanism for propionate to inhibit cell proliferation is suggested to involve its role as GPCR agonist. In human monocyte and lymphoblast cancer cell lines, Bindels and colleagues observe that the effect on cell proliferation is dependent on GPR43 activation <sup>(99)</sup>. GPR43 displays a dual coupling through G<sub>i</sub> and G<sub>q</sub> protein families. While PLC blockage does not influence cell proliferation, increase in cAMP, mediated by the inhibition of G<sub>i</sub> subunit, slightly reduces the propionate anti-proliferative effect, suggesting a mechanism dependent on
- Considering the important metabolic shift occurring in cancer cells, the production and availability of a large variety of metabolites are modified among which acetyl-CoA. Acetyl-CoA is crucial in several metabolic pathways and a fundamental cofactor for HATs. Consequently, different cell metabolites are produced, such as a large amount of lactate, which in turn could stimulate the growth of commensal bacteria and partially explain the anti-tumorigenic effect of some probiotics (100).
- Regulation of gut endocrine functions, importance on host physiology
- Among intestinal epithelial cells, enteroendocrine cells (EECs) play an important role in host physiology by secreting hormones that regulate food intake, insulin secretion and gut functions

in response to a variety of stimuli (101). Among these stimuli, fiber-rich diets or infusion with SCFAs have been associated with increased circulating levels of gut hormones (102, 103). Supporting these results, expression of butyrate receptors GPR43, GPR41 and GPR109a have been reported in enteroendocrine cells (104-106). Acute stimulation of EECs by SCFAs is shown to trigger hormones secretion such as GLP-1 and PYY. The mechanism involves GPR43 activation leading to increased intracellular calcium, corresponding to the activation of a G<sub>a</sub> coupled receptor (107). Several studies have confirmed the role of GPR43 in the EEC response to SCFAs using additional knockout models or agonists (108-110). In particular EECs, the L-cells, GPR41 is also involved in the GLP-1 secretory response as suggested by the results in GPR41 knockout animals or GPR41 agonists (106, 107). However, GPR41 stimulation also inhibits GIP secretion from glucose insulinotropic polypeptide (GIP) producing EECs (111). This inhibition of GIP-producing cells could correspond to the activation of Gi/o pathways which are mainly resulting in inhibitory responses. The exact role of GPR41 in GLP-1 secretion remains to be fully understood. The possibility of GPR41 hetero-dimerization with GPR43 has been recently highlighted and could explain a role of GPR41 in GLP-1 stimulatory activity<sup>(112)</sup>. Additionally, species differences are described in response to the different SCFAs. If propionate and acetate are strong stimuli for PYY and GLP-1 secretion in rodents at low concentrations, much higher concentrations are required to induce secretion in human (110, 113). These divergences can be explained both by the variation of SCFAs affinities to the receptor families as well as the different receptors expression levels. Indeed, GPR41 is expressed in fewer EECs in humans compared to rodents (106, 114). The role of other SCFAs receptors GPR109a, GPR42, OR51E1 and OR51E2, is still to be deciphered but some studies show that they are also enriched in some EECs subpopulations (62, 115).

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

In addition to the SCFA-dependent acute stimulation of gut hormone secretion, it emerged that SCFAs also tune EECs identity and consequently long-term hormonal production. Indeed, animals fed with fiber-rich diets have, in addition to a higher circulating gut hormone levels, an elevated number of enteroendocrine cells (102). Supporting this result, an increase differentiation of epithelial cells into L-cells by SCFAs have been reported, with a higher GLP-1, PYY and serotonin production (103, 116-120). GPR43 and GPR41 play important but different roles in the differentiation of enteroendocrine cells. GPR43 stimulation increased the number of the PYY-producing cells and *PYY* expression but not the number of GLP-1-positive cells which is dependent on GPR41 (116, 117).

Moreover, receptor-independent pathways are also involved in the expression regulation of gut hormone genes. Indeed, butyrate HDAC inhibitory activity highly increased *PYY* expression in human L-cells with a much stronger effect than GPR43 stimulation <sup>(116)</sup>. Modulation of *PYY* gene expression is associated with increased production and secretion both in basal and stimulated conditions and could explain the long-term effects of SCFAs on circulating gut hormone levels seen with fiber-enriched diets. Butyrate also impacts EECs responses to external stimuli by regulating the expression of receptors sensing exogenous molecules deriving from the microbiota. In particular, butyrate increases Toll-like receptors (TLR) expression in L-cells leading to an amplified stimulation by TLR ligands and a consequent higher NF-κB activation and butyrate-dependent *PYY* expression <sup>(121)</sup>.

Due to their important functions on host, gut hormones link SCFAs and the modulation of other gut functions such as electrolyte absorption. Indeed, PYY is strongly associated with the modulation of electrolyte and water absorption functions due to the expression of NPY receptors on epithelial cells and neuronal cells (122, 123). As SCFAs stimulate PYY release, they impact electrolyte absorption (124). Similarly, serotonin is also important in water and electrolyte absorption. SCFAs also increase serotonin production, and blockade of serotonin receptors decreases butyrate-dependent electrolyte absorption (119, 125). These results indicate that regulation of electrolytes absorption by SCFAs is mediated by multiple pathways including gut hormone modulations.

SCFAs have also been associated with tuning of intestinal transit <sup>(125)</sup>. Acute effect of SCFAs on gut motility is hormone dependent with an important role of PYY <sup>(126, 127)</sup>. Moreover, germfree animals have decreased gut motility which is partially restored by SCFAs infusion in the colonic lumen, with butyrate having the highest effect <sup>(128)</sup>. The gut motility dysfunction in germ-free mouse could be partially explained by the highly dysregulated gut endocrine functions. However, no difference could be found in non-producing serotonin mouse model using TPH1 knockout mice <sup>(128)</sup>. This suggests that serotonin might not play an important role in the SCFAs-dependent regulation of gut motility and effects previously described could be minor compared to other pathways <sup>(125)</sup>. Interestingly, SCFAs, and mostly butyrate, have a direct effect on gut motility through regulation of enteric neurons <sup>(126)</sup>. Indeed, some enteric neurons express GPR41 and can therefore respond to SCFAs <sup>(106)</sup>. Additionally, HDAC inhibition by butyrate increases gut motility on the long term by increasing the number of

acetylcholine and substance P positive neurons, highlighting the importance of distinct mechanisms triggering similar effects <sup>(129)</sup>.

Butyrate and other SCFAs are therefore important regulators of EECs functions, both by acutely stimulating gut hormone secretion, and modulating their production. Indeed, SCFAs increase EECs subpopulation cell numbers and regulate genes expression. Different mechanisms including receptor activation and HDAC inhibition are involved in these functions, highlighting the important and diverse roles of SCFAs as signaling molecules. Modulations of gut hormones participate in the many roles of SCFAs on host physiology including gut homeostasis.

### Barrier function and Immune responses

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

In the last decade, SCFAs have attracted considerable attention for their impact on host immune responses and barrier functions. SCFAs play one of their major roles by maintaining an environment favourable for commensal bacteria and controlling pathogens growth. By stabilising the transcription factor HIF, butyrate increases O<sub>2</sub> consumption by IECs favouring the physiologic hypoxia in the colon (130). Maintenance of the colonic anaerobic environment is key to favour the anaerobes commensal component of the gut microbiota and control the pathogens level such as Salmonella in a virtuous cycle (131-133). However, enteric pathogens such as Salmonella enterica serovar Typhimurium are highly adapted to the colonic environment and utilize the gut microbiota-derived butyrate to compete with resident bacteria (134). Besides effect on the O<sub>2</sub> level in the intestinal tract, butyrate promotes the epithelial barrier functions by reducing the epithelial permeability via HIF (130). Moreover, butyrate reduces epithelial permeability by the regulation of IL-10 receptor, occludin, zonulin and claudins, reinforcing the tight junctions and the trans-epithelial resistance in vitro (135, 136). Another important mechanism involved in the epithelial barrier function is the modulation of the mucus layer thickness protecting the mucosa. In the colon, MUC2 is the predominant mucin glycoprotein produced by the goblet cells. Treatment with butyrate increases MUC2 production both in vitro and in human colonic biopsies (32, 137). SCFAs enhance the epithelial barrier functions by modulating the antimicrobial peptides (AMP) secretion by the gut epithelium. Butyrate increases the level of colonic LL-37 in vitro and an in vivo (138, 139). Activation of GPR43 by butyrate induce RegIIIγ and β-defensins expression by the activation of the mTOR pathway and STAT3 phosphorylation in mouse IECs  $^{(140)}$ . The modulations of  $\beta$ -defensins in

epithelial cells relies on the inhibition of HDAC3 <sup>(141)</sup>. Interestingly, SCFAs and butyrate in particular, promote AMPs targeting both gram positive and negative bacteria.

It is now clear that gut microbiota plays an important role in intestinal homeostasis by controlling the human immune response notably by the production of SCFAs. Indeed, SCFAs have a global anti-inflammatory effect by up-regulating both anti-inflammatory and downregulating pro-inflammatory cytokines by different mechanisms and consequently promoting mucosal homeostasis (142). This anti-inflammatory effect can be mediated by IECs as binding of SCFAs to GPR43 and GPR109a induces Ca<sup>2+</sup> efflux and membrane hyperpolarization which activate the inflammasome activating protein NLRP3 thereby induce the release of IL-18 with a protective effect on DSS colitis mouse model (143). In vitro experiments demonstrate that the increase of protein acetylation by butyrate decreases IL-8 production in IECs (144). Moreover, butyrate, and to a lesser extent propionate, upregulate the production of TGF\$\beta\$1 in IECs, a cytokine promoting anti-inflammatory regulatory T cells (Treg) (145, 146). Our group have shown that butyrate acts independently of the main GPCRs, via its HDAC inhibition property and the SP1 transcription factor present on the human TGFβ1 promoter <sup>(28)</sup>. Moreover, in mice, fiber supplementation promotes vitamin A metabolism in small intestine epithelial cells by increasing RALDH-1. The production of retinoic acid by epithelial cells, the active metabolite of vitamin A, is crucial for the tolerogenic imprinting of dendritic cells (147).

The impact of SCFAs go beyond the epithelial cells, with similar mechanisms reported in macrophages and dendritic cells (DCs). In mice, macrophages stimulation with butyrate, imprints through HDAC3 inhibition, a metabolic reprogramming and elevates antimicrobial peptides. Hence, upon stimulation, AMPs belonging to the S100 family, ficolin and lysozyme are increased (148). Here again, butyrate has a stronger antimicrobial effect than propionate and no protective impact is detected with acetate. Butyrate treatment of DCs derived from human donors, decreases their capacity to present antigens and increases IL-10 production leading to a tolerogenic phenotype (149). Upon LPS treatment, butyrate induces the IL-23 production by DCs thus promoting the differentiation of naive T lymphocytes into pro-inflammatory Th17 (150). Another study shows that DCs treated with butyrate induce the differentiation of naive T lymphocytes into anti-inflammatory Tr1 producers of IL-10 (151). By regulating the transcriptional activity, butyrate decreases the inflammatory response of macrophages exposed to inflammatory microbial molecules such as LPS and induces their polarisation through a M2 anti-inflammatory phenotype (152, 153). Similarly, butyrate-dependent activation of GPR109a

increases the tolerogenic response of colonic macrophages and DCs reducing colonic inflammation and promoting homeostasis <sup>(154)</sup>. Furthermore, it has been shown that butyrate pre-treatment down-regulates nitric oxide (NO), IL-6, and IL-12 in mice independently of TLRs and GPCRs pathways. Neutrophils migration is increased upon treatment with SCFAs, in a GPR43-dependent mechanism <sup>(155)</sup>.

Regulatory T cells (Treg) are critical for limiting intestinal inflammation and have thus been subject of considerable attention to improve diseases such as inflammatory bowel disease (IBD). Many studies showed that Tregs depend on microbiota-derived signals for proper development and function (145, 146, 156, 157). Recently several groups identify SCFAs as key metabolites for promoting differentiation of naive T lymphocytes into Treg cells in the intestine (71, 145, 146, 152, 154, 158, 159). By interacting directly with naive T cells, butyrate and propionate increase the acetylation of the promoter of the transcription factor Foxp3 essential for the differentiation of Tregs, leading to an increase of Foxp3 expression (71, 152, 158). Another group suggested that propionate might induce the same changes via GPR43 (71, 159). Moreover, butyrate-dependent activation of GPR109a increases the tolerogenic response of colonic macrophages and DCs, promoting Treg and IL-10 producing T cells(154). Interestingly, SCFAs increase the TGFβ1 production by IECs via its HDAC inhibition property thus promoting the Tregs differentiation in the gut (28, 145, 146). Altogether, these studies highlight that the molecular mechanisms induced by SCFAs to control Treg-development are complex and involve many cells types involved in the tolerogenic environment such as myeloid cells and IECs.

Impact of SCFAs on other lymphocyte populations such as B cells has not been as extensively studied than their Treg counterparts. Acetate supplementation in mice increases intestinal IgA in a GPR43 dependent mechanism <sup>(160)</sup>. Dietary fibres and SCFAs enhance antibody response to bacteria by supporting B cell differentiation into plasma B cells via the increase of histone acetylation and of B cell metabolism <sup>(161, 162)</sup>. Mechanistically, it is through the downregulation of B cell AID and Blimp1, dependent on their HDAC inhibitory activity that SCFAs inhibited class-switch DNA recombination, somatic hypermutation and plasma cell differentiation. Interestingly, SCFAs also modulate the fate of B-cell producing autoantibodies and reduce autoimmunity in lupus-prone mice <sup>(162)</sup>.

#### **Conclusion:**

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

The past decade of biological research through a combination of translation-focused animal models and studies in humans has highlighted the overarching roles that the gut microbiota plays in human health. It has become clear that dysbiotic microbiota is associated with a wide range of pathologies such as obesity, diabetes, cardiovascular diseases, autoimmune diseases and neuronal disorders. Despite the lack of evidence in human, causality has been demonstrated in rodent models. Factors such as antibiotics use, modern sanitation, quality of diet and environmental factors linked with the lifestyle changes that occurred in the last century in developed societies are suggested to contribute to a decrease in the diversity of the human microbiome (163). Diet and nutritional status are important determinants in human health. Numerous studies have shown that diet modulates the composition and functions of the microbiota in humans and animal models (164-166). These interventional studies showed that microbiota composition is dynamic, can shift rapidly to dietary changes and that this shift is individual dependent and depends on the microbiota diversity of the donor. Thus, the role of diet in shaping microbiota is changing our view of the strategies to take to improve the systemic health. Indeed, it is though that nutritional interventions could manipulate the microbial ecology and consequently modulate human physiology with beneficial health outcomes. However, what constitutes an optimal health-promoting microbiota and how individuals with distinct microbiota can achieve such level of diversity are still open questions. As discussed in this review, the gut microbial metabolites, SCFAs, are well known to exert a wide beneficial impact to the host (167, 168). Hence, fiber-induced increase of SCFA-producing bacteria has been proposed to play an important role in the prevention and treatment of many diseases. Supporting this idea, clinical studies reported that prebiotics and dietary fibers increased the relative abundance of these beneficial SCFAs-producing bacteria and butyrate fermentation, leading to the improvement of type 2 diabetes and ulcerative colitis (169, 170). However, the microbiota produces a vast number of metabolites that modulate host responses, sometimes in synergy with SCFAs (121). Many studies support the benefits of increasing both the amount and the variety of dietary fibers ingested but it is difficult to establish whether it is a direct role of SCFAs or the increased bacterial diversity that impact host homeostasis. As the microbiota is a complex ecosystem, much work remains to be done to investigate fully the functions of SCFAs alone or with other beneficial metabolites in physiology and pathophysiology.

- 473 **Acknowledgements:**
- 474 The authors would like to thank all the members of the "functionality of the intestinal
- ecosystem" for helpful discussions.

476

- 477 Financial support:
- 478 This work was supported by the by Institut national de recherche pour l'agriculture,
- 1'alimentation et l'environnement (INRAE) and by grants funded by EU-FP7 METACARDIS
- 480 (HEALTH-F4-2012-305312), by the ANR FunMetagen (ANR-11-BSV6-0013).

481

- 482 **Conflict of interest:**
- The authors declare that there is no conflict of interest regarding the publication of this paper.

484

# 485 **Figure legend:**

- Figure 1: A. Functional impact of SCFA on the host. B. Mechanisms: 1: GPCR-dependent
- signaling, 2. Histone and transcription factor acetylation by SCFAs, 3. Role of butyrate as
- 488 ligand of transcription factors.

### 489 **References:**

- 490 1. Reid G, Younes JA, Van der Mei HC *et al.* (2011) Microbiota restoration: natural and supplemented recovery of human microbial communities. *Nature reviews* 492 *Microbiology* 9, 27-38.
- Lepage P, Leclerc MC, Joossens M *et al.* (2013) A metagenomic insight into our gut's microbiome. *Gut* 62, 146-158.
- Gomez de Aguero M, Ganal-Vonarburg SC, Fuhrer T *et al.* (2016) The maternal microbiota drives early postnatal innate immune development. *Science* 351, 1296-1302.
- 497 4. Rakoff-Nahoum S, Kong Y, Kleinstein SH *et al.* (2015) Analysis of gene-environment interactions in postnatal development of the mammalian intestine. *Proceedings of the National Academy of Sciences of the United States of America* 112, 1929-1936.
- 500 5. van de Guchte M, Blottiere HM Dore J (2018) Humans as holobionts: implications for prevention and therapy. *Microbiome* 6, 81.
- 502 6. Atarashi K & Honda K (2011) Microbiota in autoimmunity and tolerance. *Curr Opin Immunol* 23, 761-768.

- 7. Miyake S, Kim S, Suda W *et al.* (2015) Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters. *PloS one* 10, e0137429.
- 8. Benakis C, Brea D, Caballero S *et al.* (2016) Commensal microbiota affects ischemic stroke outcome by regulating intestinal gammadelta T cells. *Nature medicine*, 22(5): 516-23.
- 9. Qin J, Li R, Raes J *et al.* (2010) A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 464, 59-65.
- 512 10. Qin N, Yang F, Li A *et al.* (2014) Alterations of the human gut microbiome in liver cirrhosis. *Nature* 513, 59-64.
- Le Chatelier E, Nielsen T, Qin J *et al.* (2013) Richness of human gut microbiome correlates with metabolic markers. *Nature* 500, 541-546.
- 516 12. Karlsson FH, Fak F, Nookaew I *et al.* (2012) Symptomatic atherosclerosis is associated with an altered gut metagenome. *Nature communications* 3, 1245.
- 518 13. Pozuelo M, Panda S, Santiago A *et al.* (2015) Reduction of butyrate- and methane-519 producing microorganisms in patients with Irritable Bowel Syndrome. *Scientific* 520 *reports* 5, 12693.
- 521 14. Vatanen T, Franzosa EA, Schwager R *et al.* (2018) The human gut microbiome in early-522 onset type 1 diabetes from the TEDDY study. *Nature* 562, 589-594.
- 523 15. Garron ML & Henrissat B (2019) The continuing expansion of CAZymes and their families. *Curr Opin Chem Biol* 53, 82-87.
- 525 16. Duncan SH, Holtrop G, Lobley GE *et al.* (2004) Contribution of acetate to butyrate formation by human faecal bacteria. *Br J Nutr* 91, 915-923.
- 527 17. Pryde SE, Duncan SH, Hold GL *et al.* (2002) The microbiology of butyrate formation in the human colon. *FEMS Microbiol Lett* 217, 133-139.
- 529 18. Cummings JH (1981) Short chain fatty acids in the human colon. *Gut* 22, 763-779.
- 530 19. Macfarlane GT & Macfarlane S (1997) Human colonic microbiota: ecology, 531 physiology and metabolic potential of intestinal bacteria. *Scand J Gastroenterol Suppl* 532 222, 3-9.
- Dalile B, Van Oudenhove L, Vervliet B *et al.* (2019) The role of short-chain fatty acids in microbiota-gut-brain communication. *Nature reviews Gastroenterology & hepatology* 16, 461-478.
- Bourassa MW, Alim I, Bultman SJ *et al.* (2016) Butyrate, neuroepigenetics and the gut microbiome: Can a high fiber diet improve brain health? *Neurosci Lett* 625, 56-63.
- 538 22. Smith EA & Macfarlane GT (1997) Dissimilatory amino Acid metabolism in human colonic bacteria. *Anaerobe* 3, 327-337.

- 540 23. Davila AM, Blachier F, Gotteland M et al. (2013) Re-print of "Intestinal luminal
- nitrogen metabolism: role of the gut microbiota and consequences for the host".
- 542 *Pharmacol Res* 69, 114-126.
- 543 24. Flint HJ (2016) Gut microbial metabolites in health and disease. *Gut Microbes* 7, 187-544 188.
- Louis P, Hold GL Flint HJ (2014) The gut microbiota, bacterial metabolites and colorectal cancer. *Nature reviews Microbiology* 12, 661-672.
- Louis P & Flint HJ (2009) Diversity, metabolism and microbial ecology of butyrateproducing bacteria from the human large intestine. *FEMS Microbiol Lett* 294, 1-8.
- 549 27. Martin-Gallausiaux C, Larraufie P, Jarry A et al. (2018) Butyrate Produced by
- Commensal Bacteria Down-Regulates Indolamine 2,3-Dioxygenase 1 (IDO-1)
- Expression via a Dual Mechanism in Human Intestinal Epithelial Cells. Frontiers in
- *immunology* 9, 2838.
- 553 28. Martin-Gallausiaux C, Beguet-Crespel F, Marinelli L et al. (2018) Butyrate produced
- by gut commensal bacteria activates TGF-beta1 expression through the transcription
- factor SP1 in human intestinal epithelial cells. *Scientific reports* 8, 9742.
- 556 29. Belzer C, Chia LW, Aalvink S et al. (2017) Microbial Metabolic Networks at the Mucus
- Layer Lead to Diet-Independent Butyrate and Vitamin B12 Production by Intestinal
- 558 Symbionts. *mBio* 8.
- 559 30. Reichardt N, Duncan SH, Young P et al. (2014) Phylogenetic distribution of three
- pathways for propionate production within the human gut microbiota. The ISME
- *journal* 8, 1323-1335.
- 562 31. Duncan SH, Louis P, Thomson JM et al. (2009) The role of pH in determining the
- species composition of the human colonic microbiota. *Environmental microbiology* 11,
- 564 2112-2122.
- 32. Hamer HM, Jonkers D, Venema K et al. (2008) Review article: the role of butyrate on
- colonic function. *Aliment Pharmacol Ther* 27, 104-119.
- 567 33. Dostal A, Lacroix C, Bircher L et al. (2015) Iron Modulates Butyrate Production by a
- 568 Child Gut Microbiota In Vitro. *mBio* 6, e01453-01415.
- 569 34. Dostal A, Lacroix C, Pham VT et al. (2014) Iron supplementation promotes gut
- 570 microbiota metabolic activity but not colitis markers in human gut microbiota-
- 571 associated rats. *Br J Nutr* 111, 2135-2145.
- 572 35. Conn AR, Fell DI Steele RD (1983) Characterization of alpha-keto acid transport across
- 573 blood-brain barrier in rats. *Am J Physiol* 245, E253-260.
- 574 36. Frost G, Sleeth ML, Sahuri-Arisoylu M et al. (2014) The short-chain fatty acid acetate
- 575 reduces appetite via a central homeostatic mechanism. *Nature communications* 5, 3611.
- 576 37. Cummings JH, Pomare EW, Branch WJ et al. (1987) Short chain fatty acids in human
- large intestine, portal, hepatic and venous blood. *Gut* 28, 1221-1227.

- 578 38. Bergman EN (1990) Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. *Physiological reviews* 70, 567-590.
- Sivaprakasam S, Bhutia YD, Yang S *et al.* (2017) Short-Chain Fatty Acid Transporters:
   Role in Colonic Homeostasis. *Compr Physiol* 8, 299-314.
- 582 40. Sepponen K, Ruusunen M, Pakkanen JA *et al.* (2007) Expression of CD147 and monocarboxylate transporters MCT1, MCT2 and MCT4 in porcine small intestine and colon. *Vet J* 174, 122-128.
- Bloemen JG, Venema K, van de Poll MC *et al.* (2009) Short chain fatty acids exchange across the gut and liver in humans measured at surgery. *Clin Nutr* 28, 657-661.
- van der Beek CM, Bloemen JG, van den Broek MA *et al.* (2015) Hepatic Uptake of Rectally Administered Butyrate Prevents an Increase in Systemic Butyrate Concentrations in Humans. *J Nutr* 145, 2019-2024.
- McNeil NI, Cummings JH James WP (1979) Rectal absorption of short chain fatty acids in the absence of chloride. *Gut* 20, 400-403.
- Binder HJ & Mehta P (1989) Short-chain fatty acids stimulate active sodium and chloride absorption in vitro in the rat distal colon. *Gastroenterology* 96, 989-996.
- 594 45. Lutz T & Scharrer E (1991) Effect of short-chain fatty acids on calcium absorption by the rat colon. *Exp Physiol* 76, 615-618.
- 596 46. Srinivas SR, Gopal E, Zhuang L *et al.* (2005) Cloning and functional identification of slc5a12 as a sodium-coupled low-affinity transporter for monocarboxylates (SMCT2). *Biochem J* 392, 655-664.
- Coady MJ, Chang MH, Charron FM *et al.* (2004) The human tumour suppressor gene SLC5A8 expresses a Na+-monocarboxylate cotransporter. *J Physiol* 557, 719-731.
- 601 48. Gupta N, Martin PM, Prasad PD *et al.* (2006) SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. *Life Sci* 78, 2419-2425.
- Matthews JB, Hassan I, Meng S *et al.* (1998) Na-K-2Cl cotransporter gene expression and function during enterocyte differentiation. Modulation of Cl- secretory capacity by butyrate. *The Journal of clinical investigation* 101, 2072-2079.
- Musch MW, Bookstein C, Xie Y *et al.* (2001) SCFA increase intestinal Na absorption by induction of NHE3 in rat colon and human intestinal C2/bbe cells. *American journal* of physiology Gastrointestinal and liver physiology 280, G687-693.
- Amin MR, Dudeja PK, Ramaswamy K *et al.* (2007) Involvement of Sp1 and Sp3 in differential regulation of human NHE3 promoter activity by sodium butyrate and IFN-gamma/TNF-alpha. *American journal of physiology Gastrointestinal and liver physiology* 293, G374-382.

- 52. Subramanya SB, Rajendran VM, Srinivasan P *et al.* (2007) Differential regulation of cholera toxin-inhibited Na-H exchange isoforms by butyrate in rat ileum. *American journal of physiology Gastrointestinal and liver physiology* 293, G857-863.
- 617 53. Gelis L, Jovancevic N, Veitinger S *et al.* (2016) Functional Characterization of the Odorant Receptor 51E2 in Human Melanocytes. *The Journal of biological chemistry* 291, 17772-17786.
- 620 54. Puhl HL 3rd, Won YJ, Lu VB *et al.* (2015) Human GPR42 is a transcribed multisite variant that exhibits copy number polymorphism and is functional when heterologously expressed. *Scientific reports* 5, 12880.
- Le Poul E, Loison C, Struyf S et al. (2003) Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation.
   The Journal of biological chemistry 278, 25481-25489.
- 626 56. Brown AJ, Goldsworthy SM, Barnes AA *et al.* (2003) The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. *The Journal of biological chemistry* 278, 11312-11319.
- Thangaraju M, Cresci GA, Liu K *et al.* (2009) GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. *Cancer Res* 69, 2826-2832.
- Hudson BD, Tikhonova IG, Pandey SK *et al.* (2012) Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3. *The Journal of biological chemistry* 287, 41195-41209.
- 59. Dorsam RT & Gutkind JS (2007) G-protein-coupled receptors and cancer. *Nat Rev Cancer* 7, 79-94.
- 638 60. Priori D, Colombo M, Clavenzani P *et al.* (2015) The Olfactory Receptor OR51E1 Is 639 Present along the Gastrointestinal Tract of Pigs, Co-Localizes with Enteroendocrine 640 Cells and Is Modulated by Intestinal Microbiota. *PloS one* 10, e0129501.
- 641 61. Han YE, Kang CW, Oh JH *et al.* (2018) Olfactory Receptor OR51E1 Mediates GLP-1 Secretion in Human and Rodent Enteroendocrine L Cells. *J Endocr Soc* 2, 1251-1258.
- 643 62. Fleischer J, Bumbalo R, Bautze V *et al.* (2015) Expression of odorant receptor Olfr78 in enteroendocrine cells of the colon. *Cell Tissue Res* 361, 697-710.
- 645 63. Pluznick JL (2013) Renal and cardiovascular sensory receptors and blood pressure regulation. *Am J Physiol Renal Physiol* 305, F439-444.
- 647 64. Basson MD, Liu YW, Hanly AM *et al.* (2000) Identification and comparative analysis 648 of human colonocyte short-chain fatty acid response genes. *J Gastrointest Surg* 4, 501-649 512.
- 650 65. Rada-Iglesias A, Enroth S, Ameur A *et al.* (2007) Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes. *Genome Res* 17, 708-719.

- 653 66. Donohoe DR, Collins LB, Wali A *et al.* (2012) The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. *Mol Cell* 48, 612-626.
- 656 67. Candido EP, Reeves R Davie JR (1978) Sodium butyrate inhibits histone deacetylation in cultured cells. *Cell* 14, 105-113.
- 658 68. Sealy L & Chalkley R (1978) The effect of sodium butyrate on histone modification. *Cell* 14, 115-121.
- 660 69. Donohoe DR & Bultman SJ (2012) Metaboloepigenetics: interrelationships between 661 energy metabolism and epigenetic control of gene expression. *J Cell Physiol* 227, 3169-662 3177.
- Bose P, Dai Y Grant S (2014) Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. *Pharmacol Ther* 143, 323-336.
- Arpaia N, Campbell C, Fan X *et al.* (2013) Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature* 504, 451-455.
- Thakur BK, Dasgupta N, Ta A *et al.* (2016) Physiological TLR5 expression in the intestine is regulated by differential DNA binding of Sp1/Sp3 through simultaneous Sp1 dephosphorylation and Sp3 phosphorylation by two different PKC isoforms. *Nucleic Acids Res* 44, 5658-5672.
- Fellows R, Denizot J, Stellato C *et al.* (2018) Microbiota derived short chain fatty acids promote histone crotonylation in the colon through histone deacetylases. *Nature communications* 9, 105.
- 674 74. Boffa LC, Gruss RJ Allfrey VG (1981) Manifold effects of sodium butyrate on nuclear function. Selective and reversible inhibition of phosphorylation of histones H1 and H2A and impaired methylation of lysine and arginine residues in nuclear protein fractions. *The Journal of biological chemistry* 256, 9612-9621.
- Mathew OP, Ranganna K Yatsu FM (2010) Butyrate, an HDAC inhibitor, stimulates interplay between different posttranslational modifications of histone H3 and differently alters G1-specific cell cycle proteins in vascular smooth muscle cells. *Biomed Pharmacother* 64, 733-740.
- Parker MI, de Haan JB Gevers W (1986) DNA hypermethylation in sodium butyratetreated WI-38 fibroblasts. *The Journal of biological chemistry* 261, 2786-2790.
- Alex S, Lange K, Amolo T *et al.* (2013) Short-chain fatty acids stimulate angiopoietinlike 4 synthesis in human colon adenocarcinoma cells by activating peroxisome proliferator-activated receptor gamma. *Mol Cell Biol* 33, 1303-1316.
- 687 78. Marinelli L, Martin-Gallausiaux C, Bourhis J *et al.* (2019) Identification of the novel 688 role of butyrate as AhR ligand in human intestinal epithelial cells. *Scientific reports* 9, 689 643.
- Fleming SE, Choi SY Fitch MD (1991) Absorption of short-chain fatty acids from the rat cecum in vivo. *J Nutr* 121, 1787-1797.

- 692 80. Ardawi MS & Newsholme EA (1985) Fuel utilization in colonocytes of the rat. 693 *Biochem J* 231, 713-719.
- Roediger WE (1980) Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. *Gut* 21, 793-798.
- 696 82. Furuta GT, Turner JR, Taylor CT *et al.* (2001) Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. *J Exp Med* 193, 1027-1034.
- 699 83. Andriamihaja M, Chaumontet C, Tome D *et al.* (2009) Butyrate metabolism in human colon carcinoma cells: implications concerning its growth-inhibitory effect. *J Cell Physiol* 218, 58-65.
- 84. Blouin JM, Penot G, Collinet M *et al.* (2011) Butyrate elicits a metabolic switch in human colon cancer cells by targeting the pyruvate dehydrogenase complex. *Int J Cancer* 128, 2591-2601.
- Donohoe DR, Garge N, Zhang X *et al.* (2011) The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. *Cell metabolism* 13, 517-526.
- 708 86. Zambell KL, Fitch MD Fleming SE (2003) Acetate and butyrate are the major substrates for de novo lipogenesis in rat colonic epithelial cells. *J Nutr* 133, 3509-3515.
- 710 87. Park JH, Kotani T, Konno T *et al.* (2016) Promotion of Intestinal Epithelial Cell Turnover by Commensal Bacteria: Role of Short-Chain Fatty Acids. *PloS one* 11, e0156334.
- Augeron C & Laboisse CL (1984) Emergence of permanently differentiated cell clones in a human colonic cancer cell line in culture after treatment with sodium butyrate.

  Cancer Res 44, 3961-3969.
- Barnard JA & Warwick G (1993) Butyrate rapidly induces growth inhibition and differentiation in HT-29 cells. *Cell Growth Differ* 4, 495-501.
- 718 90. Kaiko GE, Ryu SH, Koues OI *et al.* (2016) The Colonic Crypt Protects Stem Cells from Microbiota-Derived Metabolites. *Cell* 167, 1137.
- 720 91. Csordas A (1996) Butyrate, aspirin and colorectal cancer. *Eur J Cancer Prev* 5, 221-721 231.
- 722 92. Sengupta S, Muir JG Gibson PR (2006) Does butyrate protect from colorectal cancer?
   723 J Gastroenterol Hepatol 21, 209-218.
- 724 93. K BA, Madhavan A, T RR *et al.* (2019) Short chain fatty acids enriched fermentation metabolites of soluble dietary fibre from Musa paradisiaca drives HT29 colon cancer cells to apoptosis. *PloS one* 14, e0216604.
- 727 94. Matthews GM, Howarth GS Butler RN (2012) Short-chain fatty acids induce apoptosis 728 in colon cancer cells associated with changes to intracellular redox state and glucose 729 metabolism. *Chemotherapy* 58, 102-109.

- Okabe S, Okamoto T, Zhao CM *et al.* (2014) Acetic acid induces cell death: an in vitro study using normal rat gastric mucosal cell line and rat and human gastric cancer and mesothelioma cell lines. *J Gastroenterol Hepatol* 29 Suppl 4, 65-69.
- 733 96. Verma SP, Agarwal A Das P (2018) Sodium butyrate induces cell death by autophagy 734 and reactivates a tumor suppressor gene DIRAS1 in renal cell carcinoma cell line 735 UOK146. *In Vitro Cell Dev Biol Anim* 54, 295-303.
- 736 97. Kim K, Kwon O, Ryu TY *et al.* (2019) Propionate of a microbiota metabolite induces cell apoptosis and cell cycle arrest in lung cancer. *Mol Med Rep* 20, 1569-1574.
- 738 98. Wang TT, Chiang AS, Chu JJ *et al.* (1998) Concomitant alterations in distribution of 70 kDa heat shock proteins, cytoskeleton and organelles in heat shocked 9L cells. *Int J Biochem Cell Biol* 30, 745-759.
- Porporato P, Dewulf EM *et al.* (2012) Gut microbiota-derived propionate reduces cancer cell proliferation in the liver. *Br J Cancer* 107, 1337-1344.
- 743 100. Casanova MR, Azevedo-Silva J, Rodrigues LR *et al.* (2018) Colorectal Cancer Cells
   744 Increase the Production of Short Chain Fatty Acids by Propionibacterium
   745 freudenreichii Impacting on Cancer Cells Survival. *Front Nutr* 5, 44.
- 746 101. Gribble FM & Reimann F (2019) Function and mechanisms of enteroendocrine cells and gut hormones in metabolism. *Nat Rev Endocrinol* 15, 226-237.
- 748 102. Cani PD, Amar J, Iglesias MA *et al.* (2007) Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes* 56, 1761-1772.
- 750 103. Samuel BS, Shaito A, Motoike T *et al.* (2008) Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. *Proceedings of the National Academy of Sciences of the United States of America* 105, 16767-16772.
- 754 104. Karaki S, Tazoe H, Hayashi H *et al.* (2008) Expression of the short-chain fatty acid receptor, GPR43, in the human colon. *J Mol Histol* 39, 135-142.
- Lu VB, Gribble FM Reimann F (2018) Free Fatty Acid Receptors in Enteroendocrine
   Cells. *Endocrinology* 159, 2826-2835.
- 758 106. Nohr MK, Pedersen MH, Gille A *et al.* (2013) GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes. *Endocrinology* 154, 3552-3564.
- 761 107. Tolhurst G, Heffron H, Lam YS *et al.* (2012) Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. *Diabetes* 61, 364-371.
- Holognini D, Tobin AB, Milligan G *et al.* (2016) The Pharmacology and Function of Receptors for Short-Chain Fatty Acids. *Mol Pharmacol* 89, 388-398.

- Hudson BD, Due-Hansen ME, Christiansen E *et al.* (2013) Defining the molecular basis
   for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor.
   The Journal of biological chemistry 288, 17296-17312.
- 769 110. Psichas A, Sleeth ML, Murphy KG *et al.* (2015) The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents.

  771 *International journal of obesity* 39, 424-429.
- The Transfer Transfer
- 774 112. Ang Z, Xiong D, Wu M *et al.* (2018) FFAR2-FFAR3 receptor heteromerization modulates short-chain fatty acid sensing. *FASEB J* 32, 289-303.
- 776 113. Chambers ES, Morrison DJ Frost G (2015) Control of appetite and energy intake by SCFA: what are the potential underlying mechanisms? *Proc Nutr Soc* 74, 328-336.
- 778 114. Tazoe H, Otomo Y, Karaki S *et al.* (2009) Expression of short-chain fatty acid receptor GPR41 in the human colon. *Biomed Res* 30, 149-156.
- 780 115. Roberts GP, Larraufie P, Richards P *et al.* (2019) Comparison of Human and Murine 781 Enteroendocrine Cells by Transcriptomic and Peptidomic Profiling. *Diabetes* 68, 1062-782 1072.
- 783 116. Larraufie P, Martin-Gallausiaux C, Lapaque N *et al.* (2018) SCFAs strongly stimulate PYY production in human enteroendocrine cells. *Scientific reports* 8, 74.
- 785 117. Brooks L, Viardot A, Tsakmaki A *et al.* (2017) Fermentable carbohydrate stimulates 786 FFAR2-dependent colonic PYY cell expansion to increase satiety. *Mol Metab* 6, 48-787 60.
- 788 118. Petersen N, Reimann F, Bartfeld S *et al.* (2014) Generation of L cells in mouse and human small intestine organoids. *Diabetes* 63, 410-420.
- 790 119. Reigstad CS, Salmonson CE, Rainey JF, 3rd *et al.* (2015) Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. *FASEB J* 29, 1395-1403.
- 793 120. Zhou J, Martin RJ, Tulley RT *et al.* (2008) Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. *Am J Physiol Endocrinol Metab* 295, E1160-1166.
- 121. Larraufie P, Dore J, Lapaque N *et al.* (2017) TLR ligands and butyrate increase Pyy expression through two distinct but inter-regulated pathways. *Cellular microbiology* 19.
- 799 122. Cox HM (2007) Neuropeptide Y receptors; antisecretory control of intestinal epithelial function. *Auton Neurosci* 133, 76-85.
- Pais R, Rievaj J, Larraufie P *et al.* (2016) Angiotensin II Type 1 Receptor-Dependent GLP-1 and PYY Secretion in Mice and Humans. *Endocrinology* 157, 3821-3831.

- Okuno M, Nakanishi T, Shinomura Y *et al.* (1992) Peptide YY enhances NaCl and water absorption in the rat colon in vivo. *Experientia* 48, 47-50.
- Fukumoto S, Tatewaki M, Yamada T *et al.* (2003) Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. *Am J Physiol Regul Integr Comp Physiol* 284, R1269-1276.
- Cherbut C, Ferrier L, Roze C *et al.* (1998) Short-chain fatty acids modify colonic motility through nerves and polypeptide YY release in the rat. *Am J Physiol* 275, G1415-1422.
- 811 127. Cuche G, Cuber JC Malbert CH (2000) Ileal short-chain fatty acids inhibit gastric motility by a humoral pathway. *American journal of physiology Gastrointestinal and liver physiology* 279, G925-930.
- Vincent AD, Wang XY, Parsons SP *et al.* (2018) Abnormal absorptive colonic motor activity in germ-free mice is rectified by butyrate, an effect possibly mediated by mucosal serotonin. *American journal of physiology Gastrointestinal and liver physiology* 315, G896-G907.
- Soret R, Chevalier J, De Coppet P *et al.* (2010) Short-chain fatty acids regulate the enteric neurons and control gastrointestinal motility in rats. *Gastroenterology* 138, 1772-1782.
- 821 130. Kelly CJ, Zheng L, Campbell EL *et al.* (2015) Crosstalk between Microbiota-Derived 822 Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier 823 Function. *Cell host & microbe* 17, 662-671.
- Faber F, Tran L, Byndloss MX *et al.* (2016) Host-mediated sugar oxidation promotes post-antibiotic pathogen expansion. *Nature* 534, 697-699.
- Litvak Y, Byndloss MX, Tsolis RM *et al.* (2017) Dysbiotic Proteobacteria expansion: a microbial signature of epithelial dysfunction. *Current opinion in microbiology* 39, 1-6.
- Rivera-Chavez F, Zhang LF, Faber F *et al.* (2016) Depletion of Butyrate-Producing Clostridia from the Gut Microbiota Drives an Aerobic Luminal Expansion of Salmonella. *Cell host & microbe* 19, 443-454.
- Bronner DN, Faber F, Olsan EE *et al.* (2018) Genetic Ablation of Butyrate Utilization Attenuates Gastrointestinal Salmonella Disease. *Cell host & microbe* 23, 266-273 e264.
- Zheng L, Kelly CJ, Battista KD *et al.* (2017) Microbial-Derived Butyrate Promotes
   Epithelial Barrier Function through IL-10 Receptor-Dependent Repression of Claudin Journal of immunology 199, 2976-2984.
- Wang HB, Wang PY, Wang X *et al.* (2012) Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription. *Dig Dis Sci* 57, 3126-3135.

- Gaudier E, Jarry A, Blottiere HM *et al.* (2004) Butyrate specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of glucose. *American journal of physiology Gastrointestinal and liver physiology* 287, G1168-1174.
- Hase K, Eckmann L, Leopard JD *et al.* (2002) Cell differentiation is a key determinant of cathelicidin LL-37/human cationic antimicrobial protein 18 expression by human colon epithelium. *Infection and immunity* 70, 953-963.
- Raqib R, Sarker P, Bergman P *et al.* (2006) Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. *Proceedings of the National Academy of Sciences of the United States of America* 103, 9178-9183.
- 249 140. Zhao Y, Chen F, Wu W *et al.* (2018) GPR43 mediates microbiota metabolite SCFA regulation of antimicrobial peptide expression in intestinal epithelial cells via activation of mTOR and STAT3. *Mucosal immunology* 11, 752-762.
- Fischer N, Sechet E, Friedman R *et al.* (2016) Histone deacetylase inhibition enhances antimicrobial peptide but not inflammatory cytokine expression upon bacterial challenge. *Proceedings of the National Academy of Sciences of the United States of America* 113, E2993-3001.
- Maslowski KM, Vieira AT, Ng A *et al.* (2009) Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. *Nature* 461, 1282-1286.
- Macia L, Tan J, Vieira AT *et al.* (2015) Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. *Nature communications* 6, 6734.
- Huang N, Katz JP, Martin DR *et al.* (1997) Inhibition of IL-8 gene expression in Caco-2 cells by compounds which induce histone hyperacetylation. *Cytokine* 9, 27-36.
- Atarashi K, Tanoue T, Oshima K *et al.* (2013) Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. *Nature* 500, 232-236.
- Atarashi K, Tanoue T, Shima T *et al.* (2011) Induction of colonic regulatory T cells by indigenous Clostridium species. *Science* 331, 337-341.
- Goverse G, Molenaar R, Macia L *et al.* (2017) Diet-Derived Short Chain Fatty Acids
   Stimulate Intestinal Epithelial Cells To Induce Mucosal Tolerogenic Dendritic Cells.
   Journal of immunology 198, 2172-2181.
- Schulthess J, Pandey S, Capitani M *et al.* (2019) The Short Chain Fatty Acid Butyrate Imprints an Antimicrobial Program in Macrophages. *Immunity* 50, 432-445 e437.
- Liu L, Li L, Min J *et al.* (2012) Butyrate interferes with the differentiation and function of human monocyte-derived dendritic cells. *Cell Immunol* 277, 66-73.
- 874 150. Berndt BE, Zhang M, Owyang SY *et al.* (2012) Butyrate increases IL-23 production by stimulated dendritic cells. *American journal of physiology Gastrointestinal and liver physiology* 303, G1384-1392.

- Kaisar MMM, Pelgrom LR, van der Ham AJ *et al.* (2017) Butyrate Conditions Human Dendritic Cells to Prime Type 1 Regulatory T Cells via both Histone Deacetylase Inhibition and G Protein-Coupled Receptor 109A Signaling. *Frontiers in immunology* 8, 1429.
- 152. Chang PV, Hao L, Offermanns S *et al.* (2014) The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition.


  Proceedings of the National Academy of Sciences of the United States of America 111, 2247-2252.
- Ji J, Shu D, Zheng M *et al.* (2016) Microbial metabolite butyrate facilitates M2 macrophage polarization and function. *Scientific reports* 6, 24838.
- Singh N, Gurav A, Sivaprakasam S *et al.* (2014) Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. *Immunity* 40, 128-139.
- Vinolo MA, Ferguson GJ, Kulkarni S *et al.* (2011) SCFAs induce mouse neutrophil chemotaxis through the GPR43 receptor. *PloS one* 6, e21205.
- 6892 156. Geuking MB, Cahenzli J, Lawson MA *et al.* (2011) Intestinal bacterial colonization induces mutualistic regulatory T cell responses. *Immunity* 34, 794-806.
- 894 157. Round JL & Mazmanian SK (2010) Inducible Foxp3+ regulatory T-cell development 895 by a commensal bacterium of the intestinal microbiota. *Proceedings of the National* 896 *Academy of Sciences of the United States of America* 107, 12204-12209.
- Furusawa Y, Obata Y, Fukuda S *et al.* (2013) Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature* 504, 446-450.
- Smith PM, Howitt MR, Panikov N *et al.* (2013) The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science* 341, 569-573.
- 901 160. Wu W, Sun M, Chen F *et al.* (2017) Microbiota metabolite short-chain fatty acid acetate 902 promotes intestinal IgA response to microbiota which is mediated by GPR43. *Mucosal* 903 *immunology* 10, 946-956.
- 904 161. Kim M, Qie Y, Park J *et al.* (2016) Gut Microbial Metabolites Fuel Host Antibody Responses. *Cell host & microbe* 20, 202-214.
- 906 162. Sanchez HN, Moroney JB, Gan H *et al.* (2020) B cell-intrinsic epigenetic modulation of antibody responses by dietary fiber-derived short-chain fatty acids. *Nature* 2008 communications 11, 60.
- 909 163. Moskowitz JE & Devkota S (2019) Determinants of Microbial Antibiotic Susceptibility: The Commensal Gut Microbiota Perspective. *Cell host & microbe* 26, 574-576.
- 912 164. David LA, Maurice CF, Carmody RN *et al.* (2014) Diet rapidly and reproducibly alters the human gut microbiome. *Nature* 505, 559-563.

- 914 165. Cotillard A, Kennedy SP, Kong LC *et al.* (2013) Dietary intervention impact on gut microbial gene richness. *Nature* 500, 585-588.
- 916 De Filippo C, Cavalieri D, Di Paola M *et al.* (2010) Impact of diet in shaping gut 917 microbiota revealed by a comparative study in children from Europe and rural Africa. 918 *Proceedings of the National Academy of Sciences of the United States of America* 107,

919 14691-14696.

928

- 920 167. Canfora EE, Jocken JW Blaak EE (2015) Short-chain fatty acids in control of body weight and insulin sensitivity. *Nat Rev Endocrinol* 11, 577-591.
- 922 168. Sanna S, van Zuydam NR, Mahajan A *et al.* (2019) Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. *Nat Genet* 51, 600-605.
- Haller D (2010) Nutrigenomics and IBD: the intestinal microbiota at the cross-road between inflammation and metabolism. *J Clin Gastroenterol* 44 Suppl 1, S6-9.
- 926 170. Zhao L, Zhang F, Ding X *et al.* (2018) Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. *Science* 359, 1151-1156.



В

